Report of Foreign Issuer (6-k)

 

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: December 2018 (Report No. 2)

 

Commission file number: 001-36578

 

BIOBLAST PHARMA LTD.

(Translation of registrant's name into English)

 

PO Box 318, Tel-Aviv, Israel 6100201

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x  Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):  ¨

 

 

 

 

 

 

 

 

 

Results of the Meeting of Shareholders of the Company

 

At the Annual and Extraordinary General Meeting of Shareholders of the Registrant held on December 27, 2018 (the “ Meeting ”), the Registrant’s shareholders approved the agenda items as originally proposed. The agenda items that were approved are described further in Exhibits 99.1 and 99.2 to the Registrant’s Report on Form 6-K submitted to the Securities and Exchange Commission on December 6, 2018.

 

This Report of Foreign Private Issuer on Form 6-K of the Registrant is incorporated by reference into the registration statement on Form F-3 (File No. 333-206032) and the registration statements on Form S-8 (File No. 333-203114 and 333-210459) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Bioblast Pharma Ltd.
	(Registrant)
	By	/s/ Dr. Dalia Megiddo
	Name: Dr. Dalia Megiddo
	Interim Chief Executive Officer

 

Date: December 27, 2018